FDA has invited Ispire Technology’s joint venture, IKE Tech, to a roundtable scheduled for February 10, 2026, to discuss manufacturing controls for electronic nicotine delivery system (ENDS) products. The invitation was issued on February 4, 2026, and will bring together 30 selected ENDS manufacturers for a focused dialogue with the agency.
IKE Tech, a joint venture that includes Ispire Technology, Touch Point Worldwide (doing business as Berify), and Chemular, is developing a blockchain‑enabled, Bluetooth‑based age‑gating component that verifies legal‑age access at the point of use. The component has filed a component pre‑market tobacco product application (PMTA) with the FDA, positioning it as a potential industry standard for flavored vaping products.
The roundtable will provide IKE Tech and Ispire with a direct forum to influence future regulatory guidance. Participation could accelerate the adoption of the age‑gating system and strengthen Ispire’s standing as a key technology supplier in the evolving ENDS market. Ispire is a founding partner in the joint venture, though the exact ownership percentage has not been disclosed.
Co‑CEO Michael Wang said the FDA’s engagement underscores that age‑gating is central to future regulation and that Ispire is committed to advancing public‑health‑aligned technology. He added that the invitation signals FDA recognition of IKE Tech’s innovation and offers a channel to shape guidance for the industry.
The FDA’s broader focus on ENDS regulation, including enforcement resources and new rules, highlights the importance of technology solutions that prevent youth access. IKE Tech’s human‑factors validation study demonstrated 100% effectiveness in preventing underage access, reinforcing the potential impact of the technology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.